Abstract. The aim of the present study was to expound on the interactions between the mitogen-activated protein kinase (MAPK) and Hippo pathway members, and to further elucidate the molecular mechanisms of melanoma tumorigenesis. Four melanoma cell lines (C32, HS695T, SK-MEL-28 and A375) were used in the present study. Western blotting was used to assess the expression levels of the MAPK and Hippo pathway effector proteins: rapidly accelerated fibrosarcoma-1 proto-oncogene, serine/threonine kinase (RAF-1); serine/threonine kinase 3 (STK3; also known as MST-2); yes-associated protein (YAP); and tafazzin (TAZ). Immunoprecipitation was used to identify interactions between the effector proteins of the Hippo and MAPK pathways. RAF-1 was knocked down in melanoma cells using siRNA transfection, and cell proliferation, migration and invasion were determined by the MTT, wound-healing and Transwell invasion assays, respectively. Additionally, the cell cycle and apoptosis were analyzed by flow cytometry 48 h after RAF-1 knockdown. We found that the expression levels of the four proteins were variable, and that the HS695T cells expressed the highest levels of RAF-1. Immunoprecipitation studies revealed that RAF-1 bound to MST-2 in melanoma cells. Knockdown of RAF-1 inhibited the expression of YAP and TAZ, but did not affect MST-2 expression. Additionally, RAF-1 knockdown in melanoma cells significantly inhibited cell proliferation, migration and invasion, and induced apoptosis in these cells. Collectively, our results indicate that the RAF-1/MST-2 interaction may be a novel link between the MAPK and Hippo pathways.
Introduction
Melanoma is the most dangerous type of skin tumor, although it accounts for less than 5% of all skin tumors. It is responsible for over 80% of all skin cancer-related deaths. In 2012, 232,000 new cases of melanoma and 55,000 melanoma-related deaths were reported worldwide (1) . Moreover, the incidence of melanoma is increasing at a rate faster than that of any other solid tumor, and is thought to be the highest in white-skinned people living at low latitudes (2) . In its advanced stages, melanoma is highly malignant, owing to its potential for distant metastasis (3) , and an extremely low 5-year survival rate (5-16%) (4) . Unfortunately, melanoma is refractory to conventional chemotherapeutics, thus, the treatment options for patients with advanced disease are limited (5) . Understanding the molecular mechanisms of melanoma may help to improve the current therapeutic strategies.
The mitogen-activated protein kinase (MAPK) signaling pathway is a key regulator of cellular growth and proliferation, and has been found to play crucial roles in the pathogenesis of melanoma. Most melanomas exhibit constitutive activation of the MAPK pathway (6) . Mutations in the rapidly accelerated fibrosarcoma isoform B (BRAF) lead to constitutive activation of the MAPK pathway and are associated with poor outcome in melanoma (7, 8) . It has been reported that more than half of the melanoma cases contain BRAF mutations (9) . Thus, a distinct approach may be to use BRAF inhibitors to extend survival in patients with metastatic melanoma (10) . However, preexisting or acquired resistance to these agents appears soon following a transient response (11) . In addition, various studies have found that BRAF inhibitors may cause acanthopapilloma, keratoacanthoma or cutaneous squamous-cell carcinoma in the early stages of treatment (11, 12) . Therefore, identification of additional core members of key molecular pathways implicated in the pathogenesis of melanoma is crucial for the design of novel therapies.
The RAF family of serine/threonine kinases is comprised of three members: CRAF (RAF-1), BRAF and ARAF (13, 14) . As aforementioned, BRAF is reportedly involved in the pathogenesis of melanoma via the MAPK pathway. Notably, RAF-1 was also found to play an important role in the activation of the MAPK pathway in melanoma (15, 16) . RAF-1 dysregulation represents a prominent resistance mechanism in melanoma (14, 17) . Furthermore, RAF-1 can bind to serine/ threonine kinase 3 (STK3), also known as MST-2, thus influencing apoptosis (18, 19) . Notably, MST-2 is one of the core components of the Hippo pathway in mammals, which is involved in cell proliferation, growth, and apoptosis (17, 20) . Alterations in the Hippo pathway have been found to be associated with tumorigenesis, including melanoma development (21, 22) . However MST-2, yes-associated protein (YAP) and tafazzin (TAZ) are also major effectors of the Hippo pathway, and have been suggested to contribute to the metastatic and invasive capacities of melanoma cells (23) . Moreover, it has been demonstrated that YAP can regulate the response of cancer cells to MAPK pathway inhibitors (24) . Tumorigenesis is a consequence of the combined action of many factors and intricate pathways. In light of the role of the MAPK and Hippo pathways and their effectors (RAF-1, MST-2, YAP and TAZ) in melanoma, we speculated that there may exist some links among these pathways via their effectors in melanoma tumorigenesis.
In the present study, we assessed the expression levels of RAF-1, MST-2, YAP and TAZ proteins of the MAPK and Hippo pathways in four melanoma cell lines and found that RAF-1 formed a complex with MST-2. We further investigated the effects of RAF-1/MST-2 interaction on melanoma cell proliferation, migration and invasion, as well as on the cell cycle and apoptosis of melanoma cells. The present study, expounds on the interactions between the MAPK and Hippo pathway members elucidating the molecular mechanisms of melanoma tumorigenesis.
Materials and methods
Cell culture. Four melanoma cell lines, including C32, HS695T, SK-MEL-28 and A375, were used in the present study. C32, HS695T and SK-MEL-28 were cultured in minimum essential medium (MeM). A375 was cultured in Dulbecco's modified eagle's medium (DMeM) containing 100 U/ml penicillin, 10% fetal bovine serum (FBS), and 100 µg/ml streptomycin. The cell lines were maintained in a humid atmosphere at 37̊C and 5% CO 2 .
Western blot analysis. After being washed with ice-cold phosphate-buffered saline (PBS), the four cell lines were lysed in whole-cell extraction buffer. Proteins (20 µl) were resolved using 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), and transferred to polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% skim milk and incubated overnight at 4̊C with primary antibodies specific to human RAF-1, YAP and TAz (sc-227, sc-15407 and sc-17130, respectively; 1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA); MST-2 (#3952; 1:1,000; Cell Signaling Technology, Boston, MA, USA); and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:1,000; Santa Cruz Biotechnology). Then, the membranes were incubated with the appropriate secondary antibodies for 2 h at 25̊C. The membranes were washed and the protein bands were visualized using 3,3'-diaminobenzidine (DAB).
Immunoprecipitation. Cells were seeded in 6-well plates and lysed with ice-cold radioimmunoprecipitation assay (RIPA) buffer. homogenates were precleared with 20 µl of Protein A-Agarose (Santa Cruz Biotechnology) at 4̊C for 1 h with rocking. RAF-1 proteins were added as bait and immunoprecipitated with MST-2 and incubated overnight at 4̊C with rocking. The bound proteins were then immunoprecipitated with Protein A-Agarose for 2 h at 4̊C. After being washed, the immune complexes were released in 15 µl of 2x SDS loading buffer by boiling at 100̊C for 5 min and resolved by SDS-PAGE. The immune complexes were then transferred to PVDF membranes and subjected to immunoblot analysis.
RAF-1 knockdown. Cells were seeded in plates 24 h before transfection. RAF-1-siRNA and negative control siRnAs (Santa Cruz Biotechnology) were transfected using Lipofectamine 2000 according to the manufacturer's protocol. The efficacy and specificity of RAF-1 knockdown were ascertained by western blot analysis.
Cell viability assay. The cell viability after RAF-1 knockdown was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Transfected cells were cultured in a 96-well plate for 48 h and 20 µl of MTT was added to each well. After incubation for 4 h, 150 µl of dimethyl sulfoxide (DMSO) was added and the optical density (OD) at 490 nm was assessed. The inhibitory rate (iR) was calculated as follows:
Cell migration assay. Wound-healing assay was used to detect the effects of RAF-1-siRNA on the migration ability of cells. Cells in three groups (RAF-1-siRNA, control-siRNA and no-siRNA control) were cultured in 6-well plates. After the cells reached 90% confluence, a wound track, ~5 mm in size, was scored in each dish. After 48 h, the cells that migrated into the wounded area were visualized and photographed. The healing rate (HR) was calculated as follows:
Healing rate (HR) (%) = [1 -(scratch area at each time-point/ scratch area at time 0)] x 100%
Cell invasion assay. The invasion assay was performed using Transwell cell culture chambers as previously described (25) . After 48 h of transfection, the cells were harvested with 0.02% ethylenediaminetetraacetic acid (EDTA), and suspended in serum-free MeM. Then, 100 µl of cell suspension at a density of 2x10 5 cells/ml was added to the upper chamber and MEM containing 20% FBS was added to the lower compartment of the Transwell. The chambers were incubated at 37̊C for 4 h, and the cells on the upper surface of the filter, which had not migrated, were removed with cotton swabs. The migrated cells on the lower surface of the filter were collected, fixed with methanol, and stained with hematoxylin. Cells in >10 random fields of view were counted at a magnification of x200, under an inverted microscope.
Cell cycle assay. The cell cycle analysis of transfected cells was performed using flow cytometry. Transfected cells were seeded into a 6-cm dish at a density of 2x10 5 cells/ml, and cultured in a 37̊C incubator for 40 h. After being washed with ice-cold PBS, the cells were fixed with ice-cold 70% ethanol for 30 min at 4̊C, and then resuspended in PBS. The suspension was filtered and stained with propidium iodide (Pi; BD Biosciences, San Jose, CA, USA) for 30 min at 4̊C in the dark. The DnA content was analyzed using flow cytometry. Three independent experiments were performed.
Cell apoptosis assay. The transfected cells were seeded in a culture dish at a density of 2x10 5 cells/ml, and cultured at 37̊C in an incubator for 40 h. After being washed twice with ice-cold PBS, the cells were resuspended in 1x binding buffer (BD Biosciences). Apoptosis of the transfected cells was quantified by staining with 5 µl of Annexin-fluorescein isothiocyanate (FiTC; BD Biosciences) and 2.5 µl of Pi. The cells were incubated on ice for 10 min in the dark and 400 µl of 1x binding buffer was added. The apoptosis rates were analyzed using flow cytometry.
Statistical analysis. Statistical analyses were performed using SPSS 15.0 (SPSS, inc., Chicago, iL, USA). Data are presented as the mean ± standard deviation (SD) from at least three independent experiments. Data were analyzed by Student's t-test (for two groups) or one-way analysis of variance (AnoVA; for three or more groups). P<0.05 was considered to indicate a statistically significant result.
Results

Expression of MAPK and Hippo pathway members in human melanoma cell lines.
The expression levels of the MAPK and Hippo pathway effector proteins, RAF-1, MST-2, YAP and TAZ, in four human melanoma cell lines were assessed by western blotting. As shown in Fig. 1A and B, the expression levels of these proteins were variable across the panel. HS695T cells expressed the highest levels of RAF-1. The expression levels were not significantly different among the proteins and the four cell types (P>0.05).
Relationship between Hippo and MAPK pathway members in melanoma. The HS695T cells expressed the highest levels of RAF-1, thus, the subsequent experiments were carried out in these cells. To determine whether there was a causal relationship between the Hippo and MAPK pathways, we performed immunoprecipitation in HS695T cells using RAF-1 as bait. The immunoprecipitation experiments revealed that RAF-1 was highly enriched with MST-2, indicating that RAF-1 bound to MST-2 in melanoma cells (Fig. 2A) . Therefore, the interaction between RAF-1 and MST-2 may provide a link between the MAPK and Hippo pathways in these cells. Furthermore, we performed siRNA-mediated RAF-1 knockdown in melanoma cells. As shown in Fig. 2B , the expression of RAF-1 decreased significantly after siRnA transfection. Additionally, as presented in Fig. 2C , the expression levels of YAP and TAZ also decreased significantly after RAF-1 knockdown. however, the expression of MST-2 did not significantly change, which further suggests that RAF-1 bound to MST-2 (Fig. 2C) . 
Effect of RAF-1 knockdown on melanoma cell viability, migration and invasion.
To determine whether the RAF-1/MST-2 complex contributed to the tumorigenicity of melanoma, we performed MTT, wound-healing and cell invasion assays. The MTT assay was used to determine cell viability after 48 h of RAF-1 knockdown. The oDs of the RAF-1-siRNA, control-siRNA and no-siRNA control groups were 0.4157±0.0763, 0.7407±0.1734 and 0.8053±0.0991, respectively (Fig. 3A) , and their iRs were 72.56, 31.42 and 17.23%, respectively (Fig. 3B ). Significant differences were found among the three groups (P=0.000), indicating that RAF-1 knockdown significantly inhibited cell viability.
Additionally, wound-healing assay was carried out to determine changes in cell migration after RAF-1 knockdown. As shown in Fig. 4A , the number of migrated cells was significantly decreased in the RAF-1-siRnA group, but significantly increased in the control-siRNA and no-siRNA control groups. The HRs of the RAF-1-siRNA, control-siRNA, and no-siRnA control groups were 27.33±2.80, 47.30±4.26 and 50.47±3.38%, respectively (Fig. 4B) , and were significantly The Transwell cell culture chambers were used to determine the effects of RAF-1 knockdown on cell invasion (Fig. 5A) . The number of invaded cells for the RAF-1-siRNA, control-siRNA, and no-siRnA control groups were 17.1±5.1, 24.1±6.2 and 26.8±5.6, respectively (Fig. 5B ). There was a significant difference between the RAF-1-siRNA and control groups (P=0.001). These findings indicate that RAF-1 knockdown significantly inhibited cell invasion.
Effect of RAF-1 knockdown on the cell cycle and apoptosis of melanoma cells.
To determine whether RAF-1 knockdown affected the cell cycle in melanoma cells, we performed flow cytometry after 48 h of RAF-1 knockdown. The results are shown in Fig. 6 and Table I . The percentages of cells in the G1 phase in the RAF-1-siRNA, control-siRNA, and no-siRNA control groups were 64.31±4.50, 65.90±2.64 and 65.82±1.02%, respectively, and the difference was not statistically significant (P=0.783). Similarly, for cells in the G2 and S phases, no significant difference was found among the three groups.
The apoptosis of melanoma cells 48 h after siRnA transfection was also detected using flow cytometry. As shown in Fig. 7A and B, the apoptosis rates of melanoma cells were 11.88±2.25, 6.32±1.54 and 4.30±0.75 for the RAF-1-siRnA, control-siRNA, and no-siRNA control groups, respectively. Significant differences were found between the control-siRnA and RAF-1-siRNA groups (P=0.006), and between the no-siRNA control and RAF-1-siRNA groups (P=0.003). These findings indicate that RAF-1 knockdown significantly increased the apoptosis rate of melanoma cells.
Discussion
The present study, investigated the interaction between MAPK and Hippo signaling pathway members (RAF-1, MST-2, YAP and TAZ) in four malignant melanoma cell lines. The results revealed that RAF-1, MST-2, YAP and TAZ were expressed in all the melanoma cells examined. However, RAF-1 and MST-2 were found to interact in HS695T cells. Furthermore, preventing the formation of the RAF-1/MST-2 complex (through knockdown of RAF-1) inhibited melanoma cell viability, migration and invasion, and promoted apoptosis. our findings suggest that in malignant melanoma, the RAF-1/MST-2 interaction may provide a functional link between the MAPK and Hippo signaling pathways. Activation of the MAPK signaling pathway, mainly owing to oncogenic mutations in proto-oncogenes such as RAF-1, plays a critical role in the promotion of melanoma cell proliferation (26) . The main function of RAF-1 is to activate mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK, a component of the MAPK cascade) by direct phosphorylation (27) . Additionally, disruption of RAF-1 leads to widespread apoptosis (28) . Notably, this additional function (i.e., controlling apoptosis) of RAF-1 is independent of MAPK and is achieved by binding to MST-2.
MST-2 has been found to interact with both wild-type and kinase-inactive RAF-1 by mass spectrometry analysis (29) . It has been demonstrated that RAF-1 controls MST-2 activity by (29) : interfering with MST-2 dimerization, thus, permitting the transphosphorylation of critical residues required for MST-2 activation (31), in addition to recruiting a phosphatase to dephosphorylate these residues. The MST-2 interaction domain is located between amino acids 150 and 303 in the RAF-1 regulatory domain (32) . Dissociation of the RAF-1/MST-2 complex is associated with MST-2 activation, and subsequent apoptosis. In a review study by Kyriakis (28) , it has been suggested that MST-2 promotes death signaling, rather than inhibiting survival signaling, which is not consistent with the present study. In the present study, RAF-1 was found to bind MST-2 in melanoma cells. The suppression of RAF-1 and subsequent prevention of the RAF-1/MST-2 complex formation not only promoted apoptosis, but also inhibited melanoma cell proliferation significantly, which is in accordance with the findings of a recent study by Romano et al (30) .
Given that RAF-1 is an effector of the MAPK signaling pathway and MST-2 is a core component of the Hippo pathway, we propose that the RAF-1/MST-2 interaction may provide a link between these two pathways. Notably, Romano et al (33) have reported that RAF-1 mutation stimulates both the Hippo and MAPK pathways, simultaneously driving apoptosis and proliferation, whereas concomitant MST-2 downregulation switches signaling to cell proliferation, transformation and survival.
The Hippo pathway plays a tumor-suppressor role and is mutated in a variety of cancers (21) . This pathway is comprised of a cascade of kinases, including MST-2, YAP and TAZ. MST-2 is an upstream regulator of this pathway, while YAP and its paralog TAZ are the downstream effectors (23) . A recent study found that YAP and TAZ contribute to the metastatic and invasive capacities of melanoma cells (23) . Lamar et al (34) have demonstrated that YAP overexpression, with exclusive nuclear localization, improves the metastatic potential of melanoma cells. Based on the results of the present study, we postulate that RAF-1 binding may inactivate MST-2, consequently inactivating the Hippo pathway, and resulting in the accumulation of YAP and TAZ. The accumulation of YAP and TAZ may subsequently activate the target genes involved in cell proliferation and invasion. Upon knockdown of RAF-1, MST-2 could be released and activated, leading to the activation of the Hippo pathway. Yu et al (35) recently found that the Hippo pathway inhibited the expression of YAP and TAZ to regulate cell proliferation, apoptosis and differentiation, thus, modulating tissue growth and homeostasis. We, therefore, speculate that the downregulation of YAP and TAZ in the present study may be attributed to the activation of the Hippo pathway. In turn, the downregulation of YAP and TAZ may be associated with the inhibition of melanoma cell invasion and metastasis. Collectively, our data provides novel evidence suggesting that endogenous RAF-1/MST-2 interaction contributes to the deregulation of the Hippo pathway and results in the metastatic behavior of melanoma cells. Moreover, the results further reveal an intricate connection between the MAPK and Hippo pathway effector molecules.
In conclusion, our results indicate that the RAF-1/MST-2 interaction may be a novel link between the MAPK and Hippo pathways. Targeting this interaction may serve as a novel approach in the treatment of melanoma. However, further studies are needed to elucidate the mechanisms underlying the crosstalk between the two pathways.
